Kratom leaf contains more than 40 naturally occurring alkaloids, but two of them do most of the pharmacological heavy lifting: mitragynine (MG) and 7-hydroxymitragynine (7-HMG). Mitragynine is the workhorse — abundant, well-studied, and responsible for much of kratom’s low-dose character. 7-HMG is the opposite story: it makes up less than 2% of the alkaloid content in raw leaf, yet animal studies suggest it’s roughly 46 times more potent than mitragynine and about 13 times more potent than morphine at mu-opioid receptors. Understanding how these two compounds relate — and how your body converts one into the other — explains a lot about why kratom behaves the way it does, and why product quality and strain selection matter so much.
The alkaloids that actually matter
Most of kratom’s 40-plus alkaloids show up in trace amounts and have limited pharmacological punch. Five compounds account for most of the action, and their proportions vary widely depending on strain, growing region, and leaf maturity. Based on published HPLC analyses, typical ranges look like this:
- Mitragynine (MG) — the dominant alkaloid, making up anywhere from 12% to 66% of total alkaloid content
- 7-Hydroxymitragynine (7-HMG) — under 2% in the raw leaf, but far more active at opioid receptors
- Paynantheine — usually the second or third most abundant compound (roughly 5–24%), acting as a smooth muscle relaxant
- Speciociliatine — a structural cousin of mitragynine with weak opioid activity (2–17%)
- Speciogynine — another smooth muscle relaxant present at moderate levels across most varieties (4–13%)
These ratios shift enough from strain to strain that they help explain why different kratom varieties feel noticeably different, even when the alkaloid list itself is nearly identical.
How mitragynine works in the body
Mitragynine is a corynantheidine-type indole alkaloid first isolated in 1921, though its full structure wasn’t confirmed until 1964. It’s the most abundant and most researched compound in kratom.
At the receptor level, mitragynine acts as a partial agonist at mu-opioid receptors — the same receptor family targeted by morphine and codeine, but with a different pharmacological signature. Partial agonists have a ceiling: their effect plateaus rather than climbing indefinitely with dose. That ceiling is one reason kratom’s dose-response curve doesn’t track with classical opioids.
Mitragynine doesn’t stop at opioid receptors, either. It also interacts with:
- Alpha-2 adrenergic receptors — the main driver behind kratom’s stimulant effects at lower doses
- Delta-opioid receptors — contributing additional pain relief
- Serotonin receptors (5-HT₂A) — linked to mood effects users often report
This spread of activity is why researchers tend to call mitragynine an “atypical opioid” — its overall effect profile can’t be pinned down to opioid receptor activity alone. A 2024 study by Obeng and colleagues confirmed mitragynine’s adrenergic receptor activity in both lab-based assays and animal behavior tests, showing that the stimulant effect at low doses is a real, measurable mechanism rather than a side note.
Pharmacokinetics of mitragynine
In humans, mitragynine’s plasma half-life runs roughly 9 to 24 hours, depending on the study and individual metabolic differences. Peak blood levels typically show up 1 to 1.5 hours after oral ingestion. The liver breaks mitragynine down mainly through the CYP3A4 enzyme, with help from CYP2D6 and CYP2C9 — and this metabolic step matters a great deal, because it’s how the body produces 7-HMG.
What makes 7-HMG different from mitragynine?
7-HMG is an oxidized version of mitragynine, present in fresh leaf at under 2% of total alkaloid content. Despite that small natural share, it has an outsized pharmacological effect because of how strongly it binds mu-opioid receptors.
Where mitragynine’s low-dose effects lean stimulant — driven largely by adrenergic activity — 7-HMG is much more focused on opioid receptors. It also crosses the blood-brain barrier more efficiently than mitragynine, which helps explain the delayed shift from stimulating to sedating effects as kratom doses increase: that lag is essentially the time it takes the liver to convert mitragynine into 7-HMG.
Distinguishing features of 7-HMG:
- Roughly 46 times more potent than mitragynine at mu-opioid receptors
- Roughly 13 times more potent than morphine in animal pain studies
- Crosses the blood-brain barrier more readily than mitragynine
- Animals trained to self-administer morphine will also self-administer 7-HMG — mitragynine, notably, does not produce this behavior
- The main driver of kratom’s pain-relieving and sedative effects at higher doses
How the liver turns mitragynine into 7-HMG
One of the more important discoveries in kratom pharmacology is that your liver converts mitragynine into 7-HMG during first-pass metabolism. CYP3A4 — the body’s primary drug-metabolizing enzyme — catalyzes this conversion.
A 2019 study by Kruegel and colleagues confirmed this happens in both mouse and human liver tissue, establishing that most of the 7-HMG a kratom user experiences comes from this in-body conversion, not from the small amount naturally present in the leaf.
This prodrug relationship has real practical consequences:
- Individual variation is partly enzyme-driven. People who metabolize CYP3A4 substrates quickly generate more 7-HMG from the same dose of kratom, which helps explain why effects vary so much from person to person.
- Other drugs can shift the ratio. Medications that inhibit CYP3A4 — ketoconazole, grapefruit compounds, fluoxetine — can increase 7-HMG production and intensify opioid-receptor effects. Drugs that induce CYP3A4, like rifampin or carbamazepine, can reduce it.
- The delayed sedation makes biochemical sense. Early effects tend to be mitragynine-driven (adrenergic, fast-onset). The later shift toward sedation and pain relief reflects the time it takes for 7-HMG to accumulate.
- Dose and effect aren’t a straight line. As more mitragynine becomes available for conversion, the body may generate disproportionately more 7-HMG than a simple dose-response model would predict.
Comparing potency: mitragynine, 7-HMG, and morphine
| Property | Mitragynine | 7-Hydroxymitragynine | Morphine |
|---|---|---|---|
| Receptor agonist type | Partial (G-protein biased) | Partial (G-protein biased) | Full agonist |
| Relative analgesic potency | 1× (reference) | ~46× vs. mitragynine | Roughly 1/13 the potency of 7-HMG |
| β-arrestin-2 recruitment | Minimal | Minimal | High |
| Natural leaf content | 12–66% | Under 2% | Not applicable (synthetic) |
| Self-administration in opioid-trained rats | Not self-administered | Readily self-administered | Readily self-administered |
| Effect on subsequent morphine intake | Prior exposure decreased intake | Prior exposure increased intake | Not applicable |
| Respiratory depression risk | Low (partial agonist ceiling) | Low to moderate | High (full agonist) |
Findings drawn from Matsumoto et al. (2006), Hemby et al. (2018), Kruegel & Grundmann (2018), and Kruegel et al. (2019).
What the abuse-potential research shows
A 2018 study led by Hemby, published in Addiction Biology, ran the first direct comparison of abuse potential between mitragynine and 7-HMG using self-administration testing in rats already trained on morphine. The results were notable:
- 7-HMG readily substituted for morphine — the rats self-administered it in a dose-dependent pattern
- Mitragynine did not substitute for morphine at any dose tested
- Rats given 7-HMG beforehand later took more morphine
- Rats given mitragynine beforehand later took less morphine, a pattern consistent with anti-addictive potential
This is one of the more consequential findings in kratom research. Since natural whole-leaf kratom is dominated by mitragynine (often 60–70% of alkaloid content) with 7-HMG well under 2%, the numbers suggest that the dominant compound in whole kratom may actually reduce opioid-seeking behavior, while concentrated or isolated 7-HMG carries real abuse risk on its own.
The practical takeaway: a product with artificially concentrated or synthetic 7-HMG carries a different risk profile than natural full-spectrum kratom, even though both might be labeled “kratom.” That’s a meaningful distinction for individual users and for regulators alike.
How alkaloid profiles vary by strain
HPLC testing has repeatedly shown that alkaloid content differs quite a bit across strain categories. One of the more thorough published datasets, from Boffa and colleagues (2018, Natural Product Communications), analyzed five commercial strains using HPLC-DAD and HPLC-MS/MS.
| Strain | Mitragynine (%) | Paynantheine (%) | Speciociliatine (%) | Speciogynine (%) | Total alkaloids (mg/g leaf) | Distinct compounds detected |
|---|---|---|---|---|---|---|
| Green Malay | 59.7 | 9.7 | 12.0 | 8.38 | 9.86 | 11 |
| White Borneo | 48.2 | 8.2 | 16.0 | 6.54 | 12.2 | 11 |
| Red Thai | 44.0 | 10.2 | 16.6 | 7.07 | 8.76 | 11 |
| Red Bali | 37.7 | 4.80 | 11.0 | 3.85 | 9.84 | 24 |
| Red Malay | 4.0 | 23.6 | 2.33 | 13.4 | 5.81 | 11 |
Data from Boffa et al. (2018). Percentages reflect the proportion of total measured alkaloids in each extract.
A few things stand out:
- Green Malay had the highest mitragynine share (59.7%) and the purest overall alkaloid profile in the study
- White Borneo delivered the most total alkaloid material per gram of leaf, even though its mitragynine percentage was lower than Green Malay’s
- Red Malay was the outlier — paynantheine (23.6%) outweighed mitragynine (4.0%), a profile unlike any other strain tested, which may explain why it feels distinct from other red strains
- Red Bali contained 24 detectable alkaloids compared to 11 in the other strains, hinting at greater chemical complexity
This kind of variation explains a common complaint among kratom users: two products sold under the same strain name from different vendors can feel quite different, because the label doesn’t capture growing conditions, processing methods, or blending.
The entourage effect
Kratom’s alkaloids don’t act alone. Several compounds present alongside mitragynine and 7-HMG have distinct — sometimes opposing — activity, which supports the idea of an “entourage effect,” where the mix of compounds produces something different from any single alkaloid acting by itself.
| Alkaloid | Typical content | Known or proposed activity |
|---|---|---|
| Paynantheine | 4.8–23.6% | Smooth muscle relaxant; modulates adrenergic activity |
| Speciociliatine | 2.3–16.6% | Weak opioid receptor activity; structural relative of mitragynine |
| Speciogynine | 3.9–13.4% | Smooth muscle relaxant; peripheral effects |
| Corynantheidine | 0.1–2.2% | Acts as an opioid receptor antagonist in some models, potentially tempering mitragynine and 7-HMG activity |
| Ajmalicine | Trace | Vasodilator, used in other contexts for circulatory conditions |
The presence of corynantheidine — an antagonist — alongside mitragynine and 7-HMG, both agonists, creates a kind of built-in chemical balance. That balance may be part of why whole-leaf kratom behaves so differently from isolated 7-HMG, and it fits with Hemby’s 2018 finding that whole-plant kratom carries a different abuse-risk profile than its most potent single compound.
Biased agonism: why it matters
When an opioid activates a mu-opioid receptor, it can trigger two different downstream pathways:
- G-protein signaling — associated with pain relief and mood effects
- β-arrestin-2 signaling — associated with respiratory depression, constipation, tolerance, and even increased pain sensitivity over time
Morphine and other classical opioids activate both pathways strongly. Mitragynine and 7-HMG lean heavily toward the G-protein pathway while barely engaging β-arrestin-2 — a property researchers call biased agonism, or functional selectivity.
That has a few implications:
- A lower ceiling for respiratory depression. Both mitragynine and 7-HMG behave as partial agonists on breathing suppression, unlike full agonists such as morphine.
- Possibly slower tolerance buildup. β-arrestin-2 is tied to receptor desensitization, which is part of how opioid tolerance develops.
- A different side-effect profile. Reduced β-arrestin-2 activity may be part of why kratom tends to cause less constipation and acute sedation than an equivalent dose of a conventional opioid.
This biased signaling profile has drawn real interest from pharmaceutical researchers, who see mitragynine’s molecular structure as a possible starting point for pain medications with fewer side effects than current opioids. A 2026 review by Grundmann and colleagues in Pharmaceuticals placed mitragynine and 7-HMG within a broader class of biased opioid-receptor modulators, quantifying their bias factors against reference opioids rather than treating “biased” as a loose descriptor. A separate 2026 study from Hemby and colleagues in Frontiers in Pharmacology dug further into binding affinity and receptor selectivity across human opioid receptor subtypes, reinforcing that mitragynine and 7-HMG are not interchangeable — the ratio between them in any given product shapes the pharmacology that follows.
It’s worth being clear-eyed here: biased agonism reduces certain risks, but it doesn’t eliminate them. Regular kratom use can still lead to physical dependence through receptor downregulation, and 7-HMG on its own still shows meaningful self-administration potential in animal studies.
Drug interaction risks
Mitragynine both gets broken down by and interferes with cytochrome P450 enzymes — mainly CYP3A4, along with CYP2D6 and CYP2C9. That dual role creates two kinds of risk:
- Other drugs can change kratom’s effects. CYP3A4 inhibitors like ketoconazole, fluoxetine, or grapefruit juice can raise mitragynine levels and boost 7-HMG production. Inducers like rifampin, carbamazepine, or St. John’s Wort can reduce both.
- Kratom can change how other drugs are metabolized. This includes benzodiazepines, many SSRIs, opioid painkillers like codeine and tramadol, statins, and macrolide antibiotics.
Combining kratom with other central nervous system depressants — particularly opioids or benzodiazepines — is the biggest safety concern here. In published case reports, most kratom-related deaths involved other depressants taken alongside kratom, not kratom by itself.
Anyone on prescription medication should mention kratom use to their doctor.
The synthetic 7-HMG problem
Some products on the market now contain artificially concentrated or fully synthetic 7-HMG. These bypass the natural balance of compounds found in whole-leaf kratom and carry meaningfully different risks.
Given the self-administration research discussed above, isolated 7-HMG — not mitragynine — appears to carry the classic opioid abuse profile. Products enriched with 7-HMG strip out the natural buffering that comes from mitragynine’s dominance and from antagonist compounds like corynantheidine.
Some warning signs of potential adulteration:
- A certificate of analysis showing 7-HMG above roughly 0.1% in a plain-leaf powder is a red flag — natural dried leaf rarely exceeds 0.02%
- Liquid shots and “enhanced” extracts are disproportionately where concentrated 7-HMG shows up
- Products advertised with extreme potency claims (like “50x extract”) without a supporting COA deserve closer scrutiny of their actual 7-HMG content
Closing thoughts
Mitragynine and 7-HMG might come from the same plant, but they behave like two different compounds with two different risk profiles. Mitragynine dominates the leaf and appears to have a moderating effect on opioid-seeking behavior; 7-HMG is scarce in nature but disproportionately powerful, and mostly reaches meaningful levels in the body through liver conversion rather than direct leaf content. That relationship — and the surrounding cast of minor alkaloids — is what makes whole-leaf kratom pharmacologically distinct from concentrated or synthetic 7-HMG products. Knowing the difference matters for anyone trying to understand what they’re actually taking.
Frequently Asked Questions
Why is 7-HMG so much more potent than mitragynine if it’s present in such small amounts?
Its binding affinity at mu-opioid receptors is around 46 times higher than mitragynine’s, so even small amounts trigger substantial receptor activation. On top of that, most of the 7-HMG a person experiences from kratom doesn’t come from the leaf itself — it’s produced in the liver from the much more abundant mitragynine. That conversion process is why 7-HMG’s impact is much bigger than its raw leaf concentration would suggest.
Does mitragynine have opioid abuse potential?
Based on the available animal research, mitragynine on its own doesn’t substitute for morphine in self-administration testing, and may even reduce later opioid-seeking behavior. That’s a sharp contrast with 7-HMG, which readily substitutes for morphine. That said, regular kratom use — which involves ongoing conversion of mitragynine to 7-HMG — can still produce physical dependence through receptor downregulation. Not having direct self-administration potential isn’t the same as having no dependence risk.
What does biased agonism mean in plain terms?
Classical opioids like morphine flip two switches at once inside the mu-opioid receptor: one that provides pain relief, and one that causes side effects like slowed breathing and severe constipation. Mitragynine and 7-HMG mostly flip the first switch while barely touching the second. That’s biased agonism — not a “safer opioid,” exactly, but one with a different balance of wanted and unwanted effects.
Why do some people respond much more strongly to kratom than others?
Individual differences in CYP3A4 enzyme activity play a big role. People who metabolize CYP3A4 substrates quickly generate more 7-HMG from the same dose of kratom, leading to stronger opioid-receptor effects. Variations in CYP2D6 activity may also contribute. Body weight, whether you’ve eaten, and other substances in your system all affect mitragynine levels and how much gets converted to 7-HMG.
Is Red Bali really different from other strains at the alkaloid level?
The available HPLC data suggests yes. Red Bali showed 24 distinct detectable alkaloids compared to 11 in other tested strains, along with different minor alkaloid ratios than other red-vein varieties. Whether this translates into a noticeably different subjective experience depends on the individual and the dose, but the chemistry does support the idea that Bali has its own character.
Does Green Malay really have more mitragynine than other strains?
In the Boffa et al. (2018) analysis, yes — Green Malay had the highest mitragynine percentage (59.7%) and the highest overall alkaloid purity of the strains tested. That may be part of why users often describe it as clean and stimulant-leaning at lower doses. Batch-to-batch variation is still significant, though, so checking a specific batch’s certificate of analysis is the only way to know actual mitragynine content.
Are extracts with concentrated 7-HMG more dangerous than plain leaf?
The pharmacological evidence points that way. Products with significantly elevated 7-HMG — whether enriched artificially or synthesized — appear to carry higher abuse potential than plain-leaf kratom, where mitragynine stays dominant. The natural antagonist compounds that help buffer 7-HMG’s effects in whole-leaf kratom may be missing or diluted in concentrated extracts. That’s a pharmacological distinction, not a marketing angle.
Can kratom alkaloids cause a positive opioid drug test?
Mitragynine and 7-HMG are structurally different from classical opioids like morphine, codeine, heroin, and oxycodone, and they typically don’t trigger false positives on standard 5-panel or 10-panel immunoassay drug tests. Specialized tests that specifically screen for mitragynine do exist, though.
